A new combo for chemo
Nature Communications
July 20, 2011
The combination of two chemotherapeutic agents reduces the growth of diffuse large B-cell lymphoma cells in a mouse model and in patients’ cells in culture. These findings, reported in Nature Communications this week, suggest that this combination therapy may be useful in treating patients with this disease.
Ronald Gartenhaus and colleagues detected the elevated expression of the DNA damage associated protein Chk2 in human diffuse large B-cell lymphoma cells and found that this correlated with the expression of another protein, ERK1/2. Using inhibitors that target the two proteins, they found that the dual treatment of primary human cancer cells induced cell death and that these chemicals also blocked tumour growth in a mouse model. This suggested that the dual treatment of the cells was more effective than the single treatment.
These findings suggest that this may be a useful approach for targeting diffuse B-cell lymphoma in the clinic.
doi: 10.1038/ncomms1404
Research highlights
-
Jul 30
Genetics: ENCODE expands the encyclopaedia of regulatory elementsNature
-
Jul 24
Drug repurposing: Large-scale screen reveals potential anti-SARS-CoV-2 drugsNature
-
Jul 23
Genomics: Six genomes provide clues to bats’ exceptional adaptationsNature
-
Jul 23
Biotechnology: A safer, rapid assay for studying SARS-CoV-2 neutralizing antibodiesNature Biotechnology
-
Jun 30
Biotechnology: Bioengineered scaffold repairs uterus and supports live births in rabbitsNature Biotechnology
-
Jun 24
Cancer: A 'fasting mimicking' diet may aid chemotherapyNature Communications
